Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics
Vertex Pharmaceuticals Incorporated (VRTX)
Today's Latest Price: $288.38 USD
Updated Jul 16 10:21am
Add VRTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
VRTX Stock Summary
- Vertex Pharmaceuticals Inc's market capitalization of $76,515,149,593 is ahead of 97.71% of US-listed equities.
- VRTX's price/sales ratio is 15.88; that's higher than the P/S ratio of 91.35% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Vertex Pharmaceuticals Inc is reporting a growth rate of 132.33%; that's higher than 91.05% of US stocks.
- Stocks that are quantitatively similar to VRTX, based on their financial statements, market capitalization, and price volatility, are AMD, AMAT, MU, REGN, and NTES.
- VRTX's SEC filings can be seen here. And to visit Vertex Pharmaceuticals Inc's official web site, go to www.vrtx.com.
VRTX Stock Price Chart Technical Analysis Charts
VRTX Price/Volume Stats
| Current price | $288.38 | 52-week high | $306.08 |
| Prev. close | $295.11 | 52-week low | $165.23 |
| Day low | $286.86 | Volume | 162,197 |
| Day high | $293.33 | Avg. volume | 1,907,711 |
| 50-day MA | $282.45 | Dividend yield | N/A |
| 200-day MA | $237.35 | Market Cap | 74.77B |
Vertex Pharmaceuticals Incorporated (VRTX) Company Bio
Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.
VRTX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $288.38 | $41312.19 | 14405% |
Below please find a table outlining a discounted cash flow forecast for VRTX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 14475.67%; returns of such proportions should be viewed with some skepticism, though. In terms of the factors that were most noteworthy in this DCF analysis for VRTX, they are:
- The compound growth rate in the free cash flow of Vertex Pharmaceuticals Inc over the past 3.5 years is 2.66%; that's better than 93.09% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 4.58% of the free cash flow producing stocks we're observing.
- VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 58.73% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 14120% |
| 1% | 14262% |
| 2% | 14405% |
| 3% | 14547% |
| 4% | 14689% |
| 5% | 14831% |
OMI, NVCR, USNU, ANIP, and CORT can be thought of as valuation peers to VRTX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...